WSU Study: Bat cells could help fight humans' most deadly diseases
Researchers are hoping that by solving the mystery of why bats can harbor viruses like hantavirus and coronavirus — pathogens that are highly dangerous to humans — without becoming ill themselves, they might also find the answer to preventing outbreaks and fighting the diseases.
Washington State University molecular virologist Michael Letko led the team studying how bats and their immune systems respond to these viruses.
'Bats are a reservoir for many pathogens that can infect humans and domestic animals, yet we lack effective tools to study bat viruses in the lab,' said Letko, an assistant professor in WSU's College of Veterinary Medicine. 'One big question is how do bats tolerate these infections? These cell lines and future research can help us uncover those mechanisms, and that could lead to new therapies for human diseases.'
According to the study published by WSU, 'A cell line is a population of cells that are cultured and maintained in a laboratory for research purposes. These cells are typically derived from a single original cell and go through a process known as immortalization, which allows them to be grown and divided indefinitely under controlled conditions, making them a valuable tool for viral research.'
Most labs have been limited to using cell lines developed more than 50 years ago, limiting their usefulness. Therefore, new lines were developed from kidney tissue of a Seba's short-tailed bat (Carollia perspicillata) that came from a colony at WSU Vancouver.
The new lines will be particularly useful for studying coronaviruses and orthohantaviruses. The orthohantaviruses family includes sin nombre virus, which is found in the western United States and recently caused a fatal infection in Whitman County, Washington.
'These viruses have the potential to impact not just our own national health, but global health, because they're found all over,' Letko said.
The study outlines one major challenge to developing useful lines — ensuring the cells maintain their ability to mount immune responses to pathogens.
'We started off with a pile of different tissues and cells, and then we went through different immortalization routes and basically started to weed them out,' Letko said. 'By the end, we had a small number of cells that were immortalized in specific ways, and those were the ones that actually still retained the properties we think are going to let us study how bats actually respond to viruses.'
Much of the research thus far has relied on cell lines from humans, rodents, or primates, which won't answer why bats tolerate viruses that make other species sick.
'We could study a virus like Ebola just fine in a human cell, and we can watch how it interacts with that immune system,' Letko said, 'but that won't help us identify the reason why bats tolerate these infections.'
According to WSU, while some bat lines have been developed in private labs, those are not often made available to other researchers. Letko wanted to ensure their work would aid future research.
'We have a lot of really good immunologists and virologists here and elsewhere, but they just don't have access to all this specialized material,' Letko said. 'That creates tiers in bat research between the groups that have access and basically everybody else who had to rely on old cell lines that were collected in the 1960s.'
To learn more, visit the WSU Insider website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
What Happens in Sierra Leone's Mpox Outbreak Affects Us All
Sentinel scientists collaborating to sequence mpox samples Credit - Kat Kendon—Kendon Photography A dangerous mpox outbreak is unfolding in Sierra Leone. In just the first week of May, cases rose by 61%, and suspected cases surged by 71%. Roughly half of all confirmed mpox cases in Africa now come from this small West African nation. The virus is moving widely, across geographies, genders, and age groups. And the virus is changing. Genomic analysis has revealed a fast-moving new variant of mpox—called G.1—that likely emerged in late November. At first it circulated silently but has since taken hold and quickly began sustained human-to-human transmission. Cases have been doubling every two weeks. Estimates suggest more than 11,000 people in Sierra Leone may already be infected. This is how outbreaks become epidemics, and mpox, as a pandemic, could be brutal. Mpox (formerly known as monkeypox) belongs to the same viral family as smallpox. It causes a disease that can be painful, disfiguring, and debilitating, particularly in children. In Sierra Leone, nearly all patients present with severe rashes, and about a quarter have required hospitalization; in some, the disease has progressed to necrotizing lesions. It's no longer rare, no longer contained to the LGBTQ community, and it has already reached more than 100 countries. Read More: Tedros Adhanom Ghebreyesus: Global-health architect Sierra Leone has been here before, at the epicenter of a disease outbreak while the world looked away. In 2014, Ebola swept through the West African region. A single mutation supercharged its spread just as it reached Sierra Leone. Tens of thousands died. Health systems collapsed. The global cost soared into the billions. The lesson? Delay is deadly. As infectious disease researchers, we've lived that lesson. For two decades, we've worked alongside colleagues across Africa and around the world to build faster, smarter ways to detect and respond to outbreaks. We were on the ground during Ebola, Zika, the COVID-19 pandemic, and recently Marburg—plus, many outbreaks that never made the news because they were stopped in time. Together, we've built technologies that track viruses in real time and trained thousands of frontline workers to use them. What once took months, we can now do in days. And now, in Sierra Leone, we are putting that progress to the test. This time, Sierra Leone isn't waiting for others to step in to do testing and sequencing—it's leading. Within days of the outbreak's escalation, local public-health teams and scientists under the leadership of Sierra Leone's National Public Health Agency—working with international partners including ourselves—expanded testing, began sequencing the virus, analyzed its evolution, and shared data in real-time. They also launched robust social mobilization and contact tracing that are helping to slow the spread. To stay ahead of the virus, teams in Sierra Leone are using powerful new tools. One is Lookout, our real-time national platform that fuses genomic, diagnostic, clinical, and epidemiological data into a single cloud-based system. As more data come in, Lookout gives health officials a live, evolving map of the outbreak, showing where it's spreading, how it's changing, and where to act next. Lookout is just one example of the infrastructure that teams in the U.S. and Africa have co-created through decades of collaboration. It belongs to a broader system called Sentinel, an outbreak detection and response network we co-lead, launched with support from the Audacious Project, a collaborative funding initiative housed at TED. Sentinel is just one part of a larger movement: scientists, engineers, public health leaders, industry partners, and frontline workers working together to build faster, smarter systems to stop outbreaks before they explode. But even the best systems can't run without support. Earlier this year, the U.S. canceled all funding to Sierra Leone and halted a $120 million initiative by the U.S. Centers for Disease Control and Prevention (CDC) aimed at strengthening epidemic preparedness in the country. The Africa CDC, U.S. CDC, World Health Organization (WHO) and other organizations continue to offer vital support, but with far fewer resources than before. Philanthropic and industry partners, including the ELMA Relief Foundation, Danaher, and Illumina, have admirably stepped in, but they cannot fill the gap alone. Today, local teams are doing so much right—with nearly everything stacked against them. The warning signs are flashing. But their resources are running out. Read More: 'This is About Children's Lives': Gavi's CEO Makes the Case for Funding the Global Vaccine Alliance It's tempting to believe this isn't our problem. But thanks to collaborative sequencing efforts, we know the G.1 variant spreading in Sierra Leone has already been detected in at least five patients across multiple U.S. states—Massachusetts, Illinois, and California—and in Europe. It may seem distant—like COVID-19 did at first—but it's not. Yes, vaccines exist, and they are expected to be effective against this new variant. But supply is limited, distribution is deeply inequitable, and the vaccines themselves present challenges—from limited clinical data and uncertain duration of protection to storage requirements—that make large-scale campaigns far from straightforward. West Africa has received only a fraction of the doses it needs. Without both vaccine access and real-time tracking, we're flying blind. Surveillance isn't a luxury. It's our first and best line of defense. Sierra Leone is showing the world what preparedness looks like. But it shouldn't have to stand alone. We can wait—again—until the virus spreads further. Or we can act now, support the leaders in Sierra Leone already responding, and get them the resources they need—like diagnostics, clinical support, vaccines, sequencing reagents, and frontline outbreak response—to save lives and cut this outbreak short. We've seen how the story of viral outbreaks can unfold. This time, with the present mpox epidemic in Sierra Leone, we still have a chance to change the ending. Disclosure: TIME's owners and co-chairs Marc and Lynne Benioff are philanthropic supporters of Sentinel. Contact us at letters@
Time Magazine
18 hours ago
- Time Magazine
Sierra Leone Is Battling an Mpox Outbreak. What Happens Next Affects Us All
A dangerous mpox outbreak is unfolding in Sierra Leone. In just the first week of May, cases rose by 61%, and suspected cases surged by 71%. Roughly half of all confirmed mpox cases in Africa now come from this small West African nation. The virus is moving widely, across geographies, genders, and age groups. And the virus is changing. Genomic analysis has revealed a fast-moving new variant of mpox—called G.1—that likely emerged in late November. At first it circulated silently but has since taken hold and quickly began sustained human-to-human transmission. Cases have been doubling every two weeks. Estimates suggest more than 11,000 people in Sierra Leone may already be infected. This is how outbreaks become epidemics, and mpox, as a pandemic, could be brutal. Mpox (formerly known as monkeypox) belongs to the same viral family as smallpox. It causes a disease that can be painful, disfiguring, and debilitating, particularly in children. In Sierra Leone, nearly all patients present with severe rashes, and about a quarter have required hospitalization; in some, the disease has progressed to necrotizing lesions. It's no longer rare, no longer contained to the LGBTQ community, and it has already reached more than 100 countries. Read More: Tedros Adhanom Ghebreyesus: Global-health architect Sierra Leone has been here before, at the epicenter of a disease outbreak while the world looked away. In 2014, Ebola swept through the West African region. A single mutation supercharged its spread just as it reached Sierra Leone. Tens of thousands died. Health systems collapsed. The global cost soared into the billions. The lesson? Delay is deadly. As infectious disease researchers, we've lived that lesson. For two decades, we've worked alongside colleagues across Africa and around the world to build faster, smarter ways to detect and respond to outbreaks. We were on the ground during Ebola, Zika, the COVID-19 pandemic, and recently Marburg—plus, many outbreaks that never made the news because they were stopped in time. Together, we've built technologies that track viruses in real time and trained thousands of frontline workers to use them. What once took months, we can now do in days. And now, in Sierra Leone, we are putting that progress to the test. This time, Sierra Leone isn't waiting for others to step in to do testing and sequencing—it's leading. Within days of the outbreak's escalation, local public-health teams and scientists under the leadership of Sierra Leone's National Public Health Agency—working with international partners including ourselves—expanded testing, began sequencing the virus, analyzed its evolution, and shared data in real-time. They also launched robust social mobilization and contact tracing that are helping to slow the spread. To stay ahead of the virus, teams in Sierra Leone are using powerful new tools. One is Lookout, our real-time national platform that fuses genomic, diagnostic, clinical, and epidemiological data into a single cloud-based system. As more data come in, Lookout gives health officials a live, evolving map of the outbreak, showing where it's spreading, how it's changing, and where to act next. Lookout is just one example of the infrastructure that teams in the U.S. and Africa have co-created through decades of collaboration. It belongs to a broader system called Sentinel, an outbreak detection and response network we co-lead, launched with support from the Audacious Project, a collaborative funding initiative housed at TED. Sentinel is just one part of a larger movement: scientists, engineers, public health leaders, industry partners, and frontline workers working together to build faster, smarter systems to stop outbreaks before they explode. But even the best systems can't run without support. Earlier this year, the U.S. canceled all funding to Sierra Leone and halted a $120 million initiative by the U.S. Centers for Disease Control and Prevention (CDC) aimed at strengthening epidemic preparedness in the country. The Africa CDC, U.S. CDC, World Health Organization (WHO) and other organizations continue to offer vital support, but with far fewer resources than before. Philanthropic and industry partners, including the ELMA Relief Foundation, Danaher, and Illumina, have admirably stepped in, but they cannot fill the gap alone. Today, local teams are doing so much right—with nearly everything stacked against them. The warning signs are flashing. But their resources are running out. It's tempting to believe this isn't our problem. But thanks to collaborative sequencing efforts, we know the G.1 variant spreading in Sierra Leone has already been detected in at least five patients across multiple U.S. states—Massachusetts, Illinois, and California—and in Europe. It may seem distant—like COVID-19 did at first—but it's not. Yes, vaccines exist, and they are expected to be effective against this new variant. But supply is limited, distribution is deeply inequitable, and the vaccines themselves present challenges—from limited clinical data and uncertain duration of protection to storage requirements—that make large-scale campaigns far from straightforward. West Africa has received only a fraction of the doses it needs. Without both vaccine access and real-time tracking, we're flying blind. Surveillance isn't a luxury. It's our first and best line of defense. Sierra Leone is showing the world what preparedness looks like. But it shouldn't have to stand alone. We can wait—again—until the virus spreads further. Or we can act now, support the leaders in Sierra Leone already responding, and get them the resources they need—like diagnostics, clinical support, vaccines, sequencing reagents, and frontline outbreak response—to save lives and cut this outbreak short. We've seen how the story of viral outbreaks can unfold. This time, with the present mpox epidemic in Sierra Leone, we still have a chance to change the ending.
Yahoo
5 days ago
- Yahoo
New coronavirus discovered in China ‘only small step' from infecting humans
A new coronavirus discovered in China is only a small step from mutating and causing another global pandemic, experts have warned. Scientists believe the variant, called HKU5-CoV-2, may infect a broader range of animals than Covid-19 – which caused millions of deaths – and may have more potential for jumping between species. US researchers fear that HKU5-CoV-2, found in China, in February, could also infect humans, leading to a widespread outbreak. The new study, published in Nature Communications, looked at a lesser-known group of coronaviruses called merbecoviruses, which includes HKU5 and MERS-CoV, which is responsible for the deadly Middle East Respiratory Syndrome. The team from Washington State University looked at how the new pathogen interacts with human cells. They found that a small change in the virus's spike protein could allow it to attach to human ACE2 cells in people's throats, mouths and noses. HKU5-CoV-2 can infect and replicate inside human cells in both the airways and gut. According to the World Health Organisation, about 35 per cent of people infected with Middle East Respiratory Syndrome die. Since 2012, some 27 countries have reported cases, leading to 858 known deaths due to the infection, which spread from camels. But when HKU5 was discovered in February, scientists warned against exaggerating the risks because it does not enter human cells as readily as Sars-CoV-2, which caused Covid-19. HKU5 was first detected in bats by scientists from the Chinese laboratory where some say Covid originated in 2019. Prof Michael Letko, a virologist who co-led the study, said: 'HKU5 viruses in particular really hadn't been looked at much, but our study shows how these viruses infect cells. 'What we also found is HKU5 viruses may be only a small step away from being able to spill over into humans.' When Covid-19 emerged it was widely blamed on markets in China where different breeds of wild animal are kept caged and often slaughtered close to other animals. Meat is sold at the open-air stalls. Critics said the markets were the perfect breeding ground for new zoonotic diseases – those that spread to humans – to emerge. The scientists, whose experiments studied how the new pathogen interacts with human cells, believe the virus would have to carry certain mutations if it were to infect humans. 'These viruses are closely related to MERS, so we have to be concerned if they ever infect humans,' Prof Letko said. 'While there's no evidence they've crossed into people yet, the potential is there and that makes them worth watching.'
